Literature DB >> 28019644

Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe.

A Del Cuvillo1, V Santos2, J Montoro3, J Bartra4, I Davila5, M Ferrer6, I Jauregui7, J Sastre8, J Mullol9, A Valero4.   

Abstract

BACKGROUND: Allergic rhinitis is a global healthcare problem due to its high prevalence, impact on individuals and socioeconomic burden for the nations. Allergic rhinitis severity evaluation is the key to a correct treatment, prevention of comorbidities and improving the quality of life of patients. This evaluation should be made with a simple, easy, fast but accurate and reliable methodology, both in a primary care and specialist setting. The visual analogue scale (VAS) meets all requirements to be the ideal tool to assess allergic rhinitis severity and has already been validated by using a single cut-off point, but this classification in two degrees of severity suffer from not allocating the patients uniformly and from giving a blind interval to classify the patients when the score is between 5 to 6 cm.
METHODOLOGY: The main objective of our study is to describe the optimal cut-off points by using a VAS to discriminate between three degrees of allergic rhinitis severity (mild, moderate, and severe) following the ARIA modified severity criteria that has been previously validated. Sensitivity, specificity, positive and negative predictive values just like receiver operating characteristic curves were used to select the best cut-off values.
RESULTS: In a cross-sectional multicentre study with 3,572 patients included we have found that VAS has a significant correlation with nasal symptom score and quality of life and that the best cut-off points to differentiate between mild, moderate an severe allergic rhinitis are a VAS score of 4 and 7, respectively.
CONCLUSIONS: Allergic rhinitis severity could be assessed in three degrees by using VAS in a simple, easy, and accurate method.

Entities:  

Mesh:

Year:  2017        PMID: 28019644     DOI: 10.4193/Rhin16.025

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  10 in total

1.  Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study.

Authors:  Ludger Klimek; David Price; Gabriella Gálffy; Melanie Emmeluth; Arkady Koltun; Ferdinand Kopietz; Duc Tung Nguyen; Ranny van Weissenbruch; Wolfgang Pohl; Hans-Christian Kuhl; Glenis Scadding; Joaquim Mullol
Journal:  Int Arch Allergy Immunol       Date:  2020-08-21       Impact factor: 2.749

2.  Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis.

Authors:  Yandan Zhou; Min Xu; Wei Gong; Xiaoming Kang; Renzhong Guo; Jie Wen; Dinggang Zhou; Manjing Wang; Dazhi Shi; Qiancheng Jing
Journal:  Mediators Inflamm       Date:  2022-06-12       Impact factor: 4.529

3.  Clinical Efficacy of Sanfeng Tongqiao Diwan in the Treatment of Allergic Rhinitis: A Randomized Controlled Trial.

Authors:  Jing Ma; Jiaying Luo; Zhangkai Cheng; Gui Chen; Zhiman Liang; Baoqing Sun; Feng Wang
Journal:  Dis Markers       Date:  2022-06-25       Impact factor: 3.464

4.  MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis.

Authors:  Ranny van Weissenbruch; Ludger Klimek; Gabriella Gálffy; Melanie Emmeluth; Arkady Koltun; Ferdinand Kopietz; Duc Tung Nguyen; Hans Christian Kuhl; Wolfgang Pohl; Glenis K Scadding; David Price; Joaquim Mullol
Journal:  J Asthma Allergy       Date:  2020-12-02

5.  Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma.

Authors:  Jef Feijen; Sven F Seys; Brecht Steelant; Dominique M A Bullens; Lieven J Dupont; Maria García-Cruz; Alejandro Jimenez-Chobillón; Désirée Larenas-Linnemann; Laura Van Gerven; Wytske J Fokkens; Ioana Agache; Peter W Hellings
Journal:  World Allergy Organ J       Date:  2020-07-01       Impact factor: 4.084

6.  A glimpse into the psychological status of E.N.T inpatients in China: A cross-sectional survey of three hospitals in different regions.

Authors:  Jun Tian; Li Li; Chun-Lei Tao; Rong-Ying Hao; Fu-Hui Huang; Xiao-Hui Ge; San-Mei Zhang
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2019-04-19

7.  Identification of Novel Biomarkers for Evaluating Disease Severity in House-Dust-Mite-Induced Allergic Rhinitis by Serum Metabolomics.

Authors:  Shaobing Xie; Hua Zhang; Zhihai Xie; Yongzhen Liu; Kelei Gao; Junyi Zhang; Shumin Xie; Fengjun Wang; Ruohao Fan; Weihong Jiang
Journal:  Dis Markers       Date:  2021-05-19       Impact factor: 3.434

8.  Circulating MIF Associated With Disease Severity and Clinical Response of Sublingual Immunotherapy in House Dust Mite-Induced Allergic Rhinitis.

Authors:  Shaobing Xie; Hua Zhang; Fengjun Wang; Zhihai Xie; Weihong Jiang; Kelei Gao
Journal:  Front Pharmacol       Date:  2021-07-08       Impact factor: 5.810

9.  Discriminating severe seasonal allergic rhinitis. Results from a large nation-wide database.

Authors:  Davide Caimmi; Nour Baiz; Shreosi Sanyal; Soutrik Banerjee; Pascal Demoly; Isabella Annesi-Maesano
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

10.  IV Brazilian Consensus on Rhinitis - an update on allergic rhinitis.

Authors:  Eulalia Sakano; Emanuel S C Sarinho; Alvaro A Cruz; Antonio C Pastorino; Edwin Tamashiro; Fábio Kuschnir; Fábio F M Castro; Fabrizio R Romano; Gustavo F Wandalsen; Herberto J Chong-Neto; João F de Mello; Luciana R Silva; Maria Cândida Rizzo; Mônica A M Miyake; Nelson A Rosário Filho; Norma de Paula M Rubini; Olavo Mion; Paulo A Camargos; Renato Roithmann; Ricardo N Godinho; Shirley Shizue N Pignatari; Tania Sih; Wilma T Anselmo-Lima; Dirceu Solé
Journal:  Braz J Otorhinolaryngol       Date:  2017-11-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.